Pro Medicus's Wild 2026: AI Fear, a Record Quarter, and a Valuation Reset

A near-perfect contract renewal record hasn't stopped the stock swinging violently between AI panic and AI opportunity.

14 Oct 2026 · 4 min read

Pro Medicus fell to around $117 in March 2026 amid a broad software sell-off driven by AI disruption fears, then staged a 74 percent quarterly rally to above $200 on a run of new contract wins that proved those fears wrong, before giving back a large chunk of the gain in July on broker downgrades with no operational setback in sight. Few stocks on the ASX have swung this hard in either direction without a change in the underlying business to match.

Caught in a fear trade despite a near-perfect scorecard

Cadence Capital described Pro Medicus as one of the market darling businesses previously on extreme valuations that had not met its fundamental criteria, until temporary headwinds produced a correction it viewed as an opportunity, initiating and adding to a position as the share price began to reverse. Tamim Funds Management disclosed it bought near $118 during the depths of what several managers called the SaaSpocalypse, while Smallco Investment Manager and Paradice Investment Management both added new positions after the February sell-off, betting the business remained intact even as its multiple had been slashed.

A record quarter of contract wins answers the skeptics

June brought the proof. LHC Capital detailed six Visage customer contracts signed during the quarter with a combined minimum value of $210 million and terms of five to seven years, three new customers and three renewals, with every renewal coming at higher prices, larger minimum commitments and adoption of additional products such as Workflow and Cardiology. Hyperion Asset Management highlighted new wins with Beth Israel Lahey Health, worth a minimum A$90 million over seven years, and TidalHealth at A$16 million over seven years, alongside renewals with Allegheny Health and other existing customers, maintaining what it called a 100 percent contract renewal track record. First Sentier Investors framed the growth in market share terms, noting Pro Medicus has gone from zero to 11 percent share of the US market and looks well on its way past 30 percent.

They're the striker that delivers every time. They don't have any bad games. There are no downgrades. They deliver every single half, first half and second half, and they tend to give you an upgrade as well through the year.

— First Sentier Investors, Article, June 2026

Several managers also pointed to AI turning from a perceived threat into a demonstrated tailwind. Solaris Investment Management and Antares Capital both noted easing concern about AI disruption to Pro Medicus's radiology imaging platform, reinforced by a financing and reseller agreement Selector Funds Management flagged with Echo IQ for cardiology algorithms covering aortic stenosis and heart failure, adding an AI-enabled product line rather than losing ground to one.

July's reversal: no news, just valuation compression

The rally unwound just as sharply as it built. Pendal Group noted the stock had climbed more than 97 percent from its February lows before broker downgrades hit in June and July, with analysts judging the re-rate had run too far and the market overly optimistic about further US market share gains and AI-driven monetisation. Antares Capital was explicit that the July decline came without a single identifiable catalyst, alongside broader weakness in high-multiple healthcare and growth technology names, and with no contract loss, downgrade or regulatory setback behind it, even as US contract wins continued.

With no contract loss, downgrade or regulatory setback identified, the decline reads as valuation compression rather than a fresh operational setback, despite continued US contract wins.

— Antares Capital, Monthly Report, July 2026

August's result settles the growth question, not the valuation one

Pendal Group described Pro Medicus's FY26 result as in line with expectations, after the market had already downgraded for currency and contract-timing reasons, with growth continuing at around 30 percent and large new contracts, product additions including Cardiology and Reporting, and a prospective AI contribution setting FY27 up well, with no meaningful change to consensus forecasts. Ziller Funds Management said it continues to hold the stock, describing the business as compelling and the founder as a reason for confidence, having used the SaaSpocalypse sell-off as an entry point it had wanted for a long time, while trimming modestly into strength and looking for opportunities to add back over the long term. The fund pointed to Pro Medicus renewing six out of six contracts as something it called unheard of in the software world.

What fund managers are watching next is whether the 100 percent contract renewal record and roughly 30 percent growth rate continue, whether AI keeps showing up as a monetisation opportunity rather than a competitive threat, and where the market ultimately settles the stock's valuation between the sub-$120 trough and the above-$200 peak it touched only months apart.